Assessing Risk Classification in Medication-Induced Diabetes during Induction Therapy in Pediatric Acute Lymphoblastic Leukemia
Medication-induced diabetes (MID) is common during induction therapy for pediatric acute lymphoblastic leukemia (ALL) and has potentially significant negative consequences. Reported risk factors for MID are variable with limited data comparing patients treated with standard-risk (SR) vs. high-risk (...
Gespeichert in:
| Veröffentlicht in: | Pediatric diabetes 2023-12, Vol.2023 (1), p.1-7 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7 |
|---|---|
| container_issue | 1 |
| container_start_page | 1 |
| container_title | Pediatric diabetes |
| container_volume | 2023 |
| creator | Ross, Katie Kulkarni, Ketan MacDonald, Tamara Pinto, Teresa |
| description | Medication-induced diabetes (MID) is common during induction therapy for pediatric acute lymphoblastic leukemia (ALL) and has potentially significant negative consequences. Reported risk factors for MID are variable with limited data comparing patients treated with standard-risk (SR) vs. high-risk (HR) regimens. This study aims to evaluate the incidence and risk factors for MID during induction in patients with ALL from the Maritimes over a 20-year period. We performed a retrospective single-center study of 262 patients (142 males, 120 females) diagnosed with ALL at IWK Health in Halifax, Nova Scotia, Canada, from 2000 to 2019. Older age, higher body mass index, greater central nervous system status, Trisomy 21, and prednisone steroid type were risk factors associated with MID in our cohort. HR patients developed significantly more complications than SR patients including MID and infection. Screening for MID should be routine during ALL induction treatment, particularly in those with HR disease. |
| doi_str_mv | 10.1155/2023/1057639 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1155_2023_1057639</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10115520231057639</sourcerecordid><originalsourceid>FETCH-LOGICAL-c294t-c113008a8a03e8b762d1c3a64ac1f9130ddda14d52f88004a678b06d203380813</originalsourceid><addsrcrecordid>eNp9kMtKxDAUhoMoOI7ufICAS62TNGmbLofxNlBRZAR35TRJncylrUmLzMpXN50pLuUszu37z4EfoUtKbimNoklIQjahJEpilh6hEWVpGkSci-O_mn2cojPnVoTQJGV8hH6mzmnnTPWJ34xb49kGfFcaCa2pK2wq_KzV0AXzSnVSK3xnoNCtdlh1tlfu53t-sdQWml2ve_U6aK2ReCq7VuNst22WdeHvt36W6W6ttwbO0UkJG6cvhjxG7w_3i9lTkL08zmfTLJBhyttAUsoIESCAMC2KJA4VlQxiDpKWqd8ppYByFYWlEIRwiBNRkFiFhDFBBGVjdHW429j6q9OuzVd1Zyv_Mmc05sxHyDx1c6CkrZ2zuswba7ZgdzkleW9x3lucDxZ7_PqAL02l4Nv8T_8C_il76g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3164343423</pqid></control><display><type>article</type><title>Assessing Risk Classification in Medication-Induced Diabetes during Induction Therapy in Pediatric Acute Lymphoblastic Leukemia</title><source>Wiley Online Library Open Access</source><source>Alma/SFX Local Collection</source><creator>Ross, Katie ; Kulkarni, Ketan ; MacDonald, Tamara ; Pinto, Teresa</creator><contributor>Kawamura, Tomoyuki</contributor><creatorcontrib>Ross, Katie ; Kulkarni, Ketan ; MacDonald, Tamara ; Pinto, Teresa ; Kawamura, Tomoyuki</creatorcontrib><description>Medication-induced diabetes (MID) is common during induction therapy for pediatric acute lymphoblastic leukemia (ALL) and has potentially significant negative consequences. Reported risk factors for MID are variable with limited data comparing patients treated with standard-risk (SR) vs. high-risk (HR) regimens. This study aims to evaluate the incidence and risk factors for MID during induction in patients with ALL from the Maritimes over a 20-year period. We performed a retrospective single-center study of 262 patients (142 males, 120 females) diagnosed with ALL at IWK Health in Halifax, Nova Scotia, Canada, from 2000 to 2019. Older age, higher body mass index, greater central nervous system status, Trisomy 21, and prednisone steroid type were risk factors associated with MID in our cohort. HR patients developed significantly more complications than SR patients including MID and infection. Screening for MID should be routine during ALL induction treatment, particularly in those with HR disease.</description><identifier>ISSN: 1399-543X</identifier><identifier>EISSN: 1399-5448</identifier><identifier>DOI: 10.1155/2023/1057639</identifier><language>eng</language><publisher>Hoboken: Hindawi</publisher><subject>Acute lymphoblastic leukemia ; Body mass index ; Central nervous system ; Diabetes mellitus ; Induction therapy ; Lymphatic leukemia ; Patients ; Pediatrics ; Prednisone ; Risk factors ; Trisomy</subject><ispartof>Pediatric diabetes, 2023-12, Vol.2023 (1), p.1-7</ispartof><rights>Copyright © 2023 Katie Ross et al.</rights><rights>2023. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c294t-c113008a8a03e8b762d1c3a64ac1f9130ddda14d52f88004a678b06d203380813</cites><orcidid>0009-0000-4795-2410 ; 0000-0002-6758-2290</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><contributor>Kawamura, Tomoyuki</contributor><creatorcontrib>Ross, Katie</creatorcontrib><creatorcontrib>Kulkarni, Ketan</creatorcontrib><creatorcontrib>MacDonald, Tamara</creatorcontrib><creatorcontrib>Pinto, Teresa</creatorcontrib><title>Assessing Risk Classification in Medication-Induced Diabetes during Induction Therapy in Pediatric Acute Lymphoblastic Leukemia</title><title>Pediatric diabetes</title><description>Medication-induced diabetes (MID) is common during induction therapy for pediatric acute lymphoblastic leukemia (ALL) and has potentially significant negative consequences. Reported risk factors for MID are variable with limited data comparing patients treated with standard-risk (SR) vs. high-risk (HR) regimens. This study aims to evaluate the incidence and risk factors for MID during induction in patients with ALL from the Maritimes over a 20-year period. We performed a retrospective single-center study of 262 patients (142 males, 120 females) diagnosed with ALL at IWK Health in Halifax, Nova Scotia, Canada, from 2000 to 2019. Older age, higher body mass index, greater central nervous system status, Trisomy 21, and prednisone steroid type were risk factors associated with MID in our cohort. HR patients developed significantly more complications than SR patients including MID and infection. Screening for MID should be routine during ALL induction treatment, particularly in those with HR disease.</description><subject>Acute lymphoblastic leukemia</subject><subject>Body mass index</subject><subject>Central nervous system</subject><subject>Diabetes mellitus</subject><subject>Induction therapy</subject><subject>Lymphatic leukemia</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Prednisone</subject><subject>Risk factors</subject><subject>Trisomy</subject><issn>1399-543X</issn><issn>1399-5448</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><recordid>eNp9kMtKxDAUhoMoOI7ufICAS62TNGmbLofxNlBRZAR35TRJncylrUmLzMpXN50pLuUszu37z4EfoUtKbimNoklIQjahJEpilh6hEWVpGkSci-O_mn2cojPnVoTQJGV8hH6mzmnnTPWJ34xb49kGfFcaCa2pK2wq_KzV0AXzSnVSK3xnoNCtdlh1tlfu53t-sdQWml2ve_U6aK2ReCq7VuNst22WdeHvt36W6W6ttwbO0UkJG6cvhjxG7w_3i9lTkL08zmfTLJBhyttAUsoIESCAMC2KJA4VlQxiDpKWqd8ppYByFYWlEIRwiBNRkFiFhDFBBGVjdHW429j6q9OuzVd1Zyv_Mmc05sxHyDx1c6CkrZ2zuswba7ZgdzkleW9x3lucDxZ7_PqAL02l4Nv8T_8C_il76g</recordid><startdate>20231216</startdate><enddate>20231216</enddate><creator>Ross, Katie</creator><creator>Kulkarni, Ketan</creator><creator>MacDonald, Tamara</creator><creator>Pinto, Teresa</creator><general>Hindawi</general><general>Wiley Subscription Services, Inc</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><orcidid>https://orcid.org/0009-0000-4795-2410</orcidid><orcidid>https://orcid.org/0000-0002-6758-2290</orcidid></search><sort><creationdate>20231216</creationdate><title>Assessing Risk Classification in Medication-Induced Diabetes during Induction Therapy in Pediatric Acute Lymphoblastic Leukemia</title><author>Ross, Katie ; Kulkarni, Ketan ; MacDonald, Tamara ; Pinto, Teresa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c294t-c113008a8a03e8b762d1c3a64ac1f9130ddda14d52f88004a678b06d203380813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acute lymphoblastic leukemia</topic><topic>Body mass index</topic><topic>Central nervous system</topic><topic>Diabetes mellitus</topic><topic>Induction therapy</topic><topic>Lymphatic leukemia</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Prednisone</topic><topic>Risk factors</topic><topic>Trisomy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ross, Katie</creatorcontrib><creatorcontrib>Kulkarni, Ketan</creatorcontrib><creatorcontrib>MacDonald, Tamara</creatorcontrib><creatorcontrib>Pinto, Teresa</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Pediatric diabetes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ross, Katie</au><au>Kulkarni, Ketan</au><au>MacDonald, Tamara</au><au>Pinto, Teresa</au><au>Kawamura, Tomoyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessing Risk Classification in Medication-Induced Diabetes during Induction Therapy in Pediatric Acute Lymphoblastic Leukemia</atitle><jtitle>Pediatric diabetes</jtitle><date>2023-12-16</date><risdate>2023</risdate><volume>2023</volume><issue>1</issue><spage>1</spage><epage>7</epage><pages>1-7</pages><issn>1399-543X</issn><eissn>1399-5448</eissn><abstract>Medication-induced diabetes (MID) is common during induction therapy for pediatric acute lymphoblastic leukemia (ALL) and has potentially significant negative consequences. Reported risk factors for MID are variable with limited data comparing patients treated with standard-risk (SR) vs. high-risk (HR) regimens. This study aims to evaluate the incidence and risk factors for MID during induction in patients with ALL from the Maritimes over a 20-year period. We performed a retrospective single-center study of 262 patients (142 males, 120 females) diagnosed with ALL at IWK Health in Halifax, Nova Scotia, Canada, from 2000 to 2019. Older age, higher body mass index, greater central nervous system status, Trisomy 21, and prednisone steroid type were risk factors associated with MID in our cohort. HR patients developed significantly more complications than SR patients including MID and infection. Screening for MID should be routine during ALL induction treatment, particularly in those with HR disease.</abstract><cop>Hoboken</cop><pub>Hindawi</pub><doi>10.1155/2023/1057639</doi><tpages>7</tpages><orcidid>https://orcid.org/0009-0000-4795-2410</orcidid><orcidid>https://orcid.org/0000-0002-6758-2290</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1399-543X |
| ispartof | Pediatric diabetes, 2023-12, Vol.2023 (1), p.1-7 |
| issn | 1399-543X 1399-5448 |
| language | eng |
| recordid | cdi_crossref_primary_10_1155_2023_1057639 |
| source | Wiley Online Library Open Access; Alma/SFX Local Collection |
| subjects | Acute lymphoblastic leukemia Body mass index Central nervous system Diabetes mellitus Induction therapy Lymphatic leukemia Patients Pediatrics Prednisone Risk factors Trisomy |
| title | Assessing Risk Classification in Medication-Induced Diabetes during Induction Therapy in Pediatric Acute Lymphoblastic Leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T15%3A47%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessing%20Risk%20Classification%20in%20Medication-Induced%20Diabetes%20during%20Induction%20Therapy%20in%20Pediatric%20Acute%20Lymphoblastic%20Leukemia&rft.jtitle=Pediatric%20diabetes&rft.au=Ross,%20Katie&rft.date=2023-12-16&rft.volume=2023&rft.issue=1&rft.spage=1&rft.epage=7&rft.pages=1-7&rft.issn=1399-543X&rft.eissn=1399-5448&rft_id=info:doi/10.1155/2023/1057639&rft_dat=%3Cproquest_cross%3E10115520231057639%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3164343423&rft_id=info:pmid/&rfr_iscdi=true |